Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/07/25
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial MarketsPRNewsWire • 07/31/25
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia AreataPRNewsWire • 07/29/25
Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesPRNewsWire • 07/02/25
NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis StudyZacks Investment Research • 06/25/25
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?Zacks Investment Research • 06/24/25
Nektar Therapeutics Launches By Triple Digits On Eczema Grand SlamInvestors Business Daily • 06/24/25
REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic DermatitisPRNewsWire • 06/24/25
Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025PRNewsWire • 06/23/25
Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POCSeeking Alpha • 06/11/25
AMBROSIA & NEKTAR Introduces Premium High-End Organic Food from Greece with a Commitment to Purity and ProvenanceGlobeNewsWire • 06/10/25
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor ConferencePRNewsWire • 05/13/25